Pulmonary arterial hypertension
- 1 January 2006
- journal article
- review article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 38 (2), 95-110
- https://doi.org/10.1080/07853890600622143
Abstract
Pulmonary arterial hypertension is a disease of the small pulmonary arteries characterized by vascular narrowing and increased pulmonary vascular resistance, which eventually leads to right ventricular failure. Vasoconstriction, vascular proliferation, remodeling of the pulmonary vessels, and thrombosis are all contributing factors to the increased vascular resistance seen in this disease. Pulmonary arterial hypertension develops as a sporadic disease (idiopathic), as an inherited disorder (familial), or in association with certain conditions (collagen vascular diseases, portal hypertension, human immunodeficiency virus infection, congenital systemic‐to‐pulmonary shunts, ingestion of drugs or dietary products, or persistent fetal circulation). The pathogenesis of pulmonary arterial hypertension is a complicated, multifactorial process. It seems doubtful that any one factor alone is sufficient to activate the necessary pathways leading to the development of this disease. Rather, clinically apparent pulmonary arterial hypertension most likely develops after a second insult occurs in an individual who is already susceptible owing to genetic factors, environmental exposures, or acquired disorders. Currently, there is no cure for pulmonary arterial hypertension but several novel therapeutic options are now available that can improve symptoms and increase survival.Keywords
This publication has 139 references indexed in Scilit:
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Clinical classification of pulmonary hypertensionJournal of the American College of Cardiology, 2004
- Mechanisms of TGF-β Signaling from Cell Membrane to the NucleusCell, 2003
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Hypoxic pulmonary vasoconstrictionGeneral Pharmacology: The Vascular System, 1999
- Fatal Pulmonary Hypertension Associated with Short-Term Use of Fenfluramine and PhentermineNew England Journal of Medicine, 1997
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Short-term effectiveness of nifedipine in secondary pulmonary hypertensionThe American Journal of Cardiology, 1993
- Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flowThe American Journal of Cardiology, 1993
- Primary pulmonary hypertension: natural history and the importance of thrombosis.Circulation, 1984